✦ LIBER ✦

Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck : An Eastern Cooperative Oncology Group trial (PA390)

✍ Scribed by Arlene A. Forastiere; Darleen Shank; Donna Neuberg; Samuel G. Taylor IV; Ronald C. DeConti; George Adams

Publisher: John Wiley and Sons
Year: 1998
Tongue: English
Weight: 68 KB
Volume: 82
Category: Article
ISSN: 0008-543X
DOI: 10.1002/(sici)1097-0142(19980601)82:11<2270::aid-cncr24>3.0.co;2-q

No coin nor oath required. For personal study only.

✦ Synopsis

The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

📜 SIMILAR VOLUMES

An eastern cooperative oncology group ph

An eastern cooperative oncology group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma

✍ Robert S. Witte; Paul Elson; Janardan Khandakar; Donald L. Trump 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 359 KB 👁 2 views

## Background. Trimetrexate is an antifol that differs from methotrexate in ways that may be clinically important. Because methotrexate has activity in advanced bladder cancer, this trial was initiated.

Phase II trial of trimetrexate for patie

Phase II trial of trimetrexate for patients with advanced gastric carcinoma : An Eastern Cooperative Oncology Group Study (E1287)

✍ Ramesh K. Ramanathan; Stuart Lipsitz; Robert F. Asbury; Raman Qazi; Bernard R. G 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB 👁 2 views

## BACKGROUND. A Phase II study was conducted to evaluate the response, duration of response, and duration of survival of patients with measurable gastric carcinoma treated with trimetrexate (TMTX) who had not had prior chemotherapy. ## METHODS. Thirty-three patients with unresectable or metast

Taxol in advanced, hormone-refractory ca

Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the eastern cooperative oncology group

✍ Bruce J. Roth; Patrick J. Loehrer; Beow Yong Yeap; George Wilding; Basil Kasimis 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 440 KB 👁 2 views

Ifosfamide, paclitaxel, and cisplatin fo

Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract : Final report of a Phase II trial evaluating two dosing schedules

✍ Dean F. Bajorin; John A. McCaffrey; Paul M. Dodd; Susan Hilton; Madhu Mazumdar; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 1 views

## BACKGROUND. A combination regimen of ifosfamide, paclitaxel, and cisplatin (ITP), recycled every 4 weeks, was reported in the treatment of previously untreated patients with advanced transitional cell carcinoma (TCC). This study sought to examine ITP at 3-week intervals to assess its feasibility

Vinblastine, ifosfamide, and gallium nit

Vinblastine, ifosfamide, and gallium nitrate—an active new regimen in patients with advanced carcinoma of the urothelium : A Phase II trial of the Eastern Cooperative Oncology Group (E5892)

✍ Robert Dreicer; Kathleen J. Propert; Bruce J. Roth; Lawrence H. Einhorn; Patrick 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 2 views

vinblastine, ifosfamide, and gallium nitrate (VIG) as first-line chemotherapy in patients with locally advanced or metastatic carcinoma of the

A phase II trial of cisplatin, methotrex

A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck

✍ Francesco Caponigro; Pasquale Comella; Paolo Marcolin; Francesco Russo Spena; Ma 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 2 views

## Background: Induction chemotherapy in locoregionally advanced squamous cell carcinoma of the head and neck (scchn) might improve survival with respect to radiation therapy alone. furthermore, chemotherapy represents the only therapeutic option in metastatic head and neck carcinoma. ## Methods: